Year: 2019
Type: conference-abstract
Abstract: Engineered T cells that encode transgenic T cell receptors (TCR) or chimeric antigen receptors (CAR) are increasingly being tested is a new modality for cancer immunotherapy. In this presentation we will review emerging patterns of efficacy and toxicity after adoptive cell transfer (ACT), with a focus on blood cancers. Striking efficacy has been observed in acute and chronic B cell leukemia and lymphoma. More unexpectedly, strong antitumor effects are being observed in multiple trials in patients with advanced refractory and relapsed myeloma. In some cases, toxicity has been predicted in preclinical models. In other cases, toxicity was only uncovered after results from Phase 1 clinical trial results were in hand. Onset of toxicity can be immediately observed following infusion of cells or maybe delayed. Toxicity usually occurs coincident with peak (Cmax) levels of adoptively transferred cells. Today with more than 1,000 patients having been infused with genetically engineered human T cells, genotoxicity has not been reported. To date, the induction of irAE appears to be less than with checkpoint therapies, although more experience with ACT is required to determine the ultimate incidence of autoimmune toxicities. Keywords: T-cell receptor (TCR). Disclosures: June, C: Research Funding: Parker Institute for Cancer Immunotherapy, NIH/NCI, Tmunity Therapeutics.
Source: Hematological Oncology
DOI: 10.1002/hon.2629
Author: C.H. June
Institution: University of Pennsylvania
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2949188704